Cargando…
Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis
Empagliflozin (EMPA) is a novel sodium-glucose cotransporter 2 inhibitor (SGLT2i) that produces protective cardiovascular-renal outcomes in patients with diabetes. However, the effects of EMPA on obesity-related kidney disease have not been determined. The heme oxygenase-1 (HO-1)–adiponectin axis is...
Autores principales: | Ye, Tongtong, Zhang, Jingwen, Wu, Di, Shi, Junfeng, Kuang, Zengguang, Ma, Yuting, Xu, Qian, Chen, Bing, Kan, Chengxia, Sun, Xiaodong, Han, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248377/ https://www.ncbi.nlm.nih.gov/pubmed/35784553 http://dx.doi.org/10.3389/fendo.2022.907984 |
Ejemplares similares
-
Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice
por: Shi, Junfeng, et al.
Publicado: (2022) -
Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
por: Ma, Yuting, et al.
Publicado: (2021) -
Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
por: Ma, Yuting, et al.
Publicado: (2022) -
Role of the NLRP3 Inflammasome in Preeclampsia
por: Shirasuna, Koumei, et al.
Publicado: (2020) -
Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
por: Kan, Chengxia, et al.
Publicado: (2021)